OASIS Platform
Osteoporosis (lead focus)
PreclinicalActive
Key Facts
About Skeletalis
Skeletalis is an early-stage biotech (founded 2021) advancing a novel, targeted delivery platform called OASIS (Osteoclast-Activated Skeletal Intervention System) for bone disorders, starting with osteoporosis. The company recently raised $8M in funding and is building a small team to advance its platform, which aims to overcome a key limitation of current anti-resorptive therapies by inhibiting pathological bone loss without shutting down healthy bone turnover. Led by its inventor-founders and backed by a lead investor, Skeletalis is positioned to address a significant unmet need in the large musculoskeletal market.
View full company profile